Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression

Journal of Hematology and Oncology

Volumn 5, Issue , 2012, Pages

  Chang, David Z ^a,b   Ma, Ying ^a   Ji, Baoan ^a   Liu, Yan ^a   Hwu, Patrick ^a   Abbruzzese, James L ^a   Logsdon, Craig ^a   Wang, Huamin ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Virginia Oncology Associates   (United States)

Author keywords

CDC20; Pancreatic cancer; Prognosis; Progression; Tumorigenesis

Indexed keywords

CELL CYCLE PROTEIN 20; CDC20 PROTEIN, HUMAN; CELL CYCLE PROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TUMOR DIFFERENTIATION; ADENOCARCINOMA; CASE CONTROL STUDY; CELL DIFFERENTIATION; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; UPREGULATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CASE-CONTROL STUDIES; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84859193216     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-5-15     Document Type: Article

References (26)

1. Cancer statistics, 2007. Jemal A, Siegel R, Ward E, Murray T, Xu J, (Pubitemid 46148091)
2. American Cancer Society. Cancer Facts & Figures 2007 22497061
3. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Carpelan-Holmstrom M, Nordling S, Pukkala E, Sankila R, Luttges J, Kloppel G, Haglund C, Gut 2005 54 385 387 10.1136/gut.2004.047191 15710987 (Pubitemid 40299095)
4. Recent advances in gastrointestinal oncology-updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology. Javle M, Hsueh CT, J Hematol Oncol 2010 3 11 10.1186/1756-8722-3-11 20331897
5. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. Hu J, Zhao G, Wang HX, Tang L, Xu YC, Ma Y, Zhang FC, J Hematol Oncol 2011 4 11 10.1186/1756-8722-4-11 21439076
6. Dysregulation of miR-15a and miR-214 in human pancreatic cancer. Zhang XJ, Ye H, Zeng CW, He B, Zhang H, Chen YQ, J Hematol Oncol 2010 3 46 10.1186/1756-8722-3-46 21106054
7. Evolving Diagnostic and Treatment Strategies for Pancreatic Neuroendocrine Tumors. Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J, J Hematol Oncol 2011 4 29 10.1186/1756-8722-4-29 21672194
8. A novel mammalian protein, p55CDC, present in dividing cells is associated with protein kinase activity and has homology to the Saccharomyces cerevisiae cell division cycle proteins Cdc20 and Cdc4. Weinstein J, Jacobsen FW, Hsu-Chen J, Wu T, Baum LG, Mol Cell Biol 1994 14 3350 3363 7513050 (Pubitemid 24132747)
9. Direct binding of CDC20 protein family members activates the anaphase-promoting complex in mitosis and G1. Fang G, Yu H, Kirschner MW, Molec Cell 1998 2 163 171 10.1016/S1097-2765(00)80126-4 9734353 (Pubitemid 128373642)
10. Cell biology: the checkpoint brake relieved. Peters J-M, Nature 2007 446 868 869 10.1038/446868a 17443175 (Pubitemid 46633155)
11. The spindle checkpoint, aneuploidy, and cancer. Bharadwaj R, Yu H, Oncogene 2004 23 2016 2027 10.1038/sj.onc.1207374 15021889 (Pubitemid 38496731)
12. DNA damage induced p53 downregulates Cdc20 by direct binding to its promoter causing chromatin remodeling. Banerjee T, Nath S, Roychoudhury S, Nucleic Acids Res 2009 37 2688 2698 10.1093/nar/gkp110 19273532
13. Effects of histone deacetylase inhibitors on p55CDC/Cdc20 expression in HT29 cell line. Iacomino G, Medici MC, Napoli D, Russo GL, J Cell Biochem 2006 99 1122 1131 10.1002/jcb.21014 16795040 (Pubitemid 44673969)
14. Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Kim JMSH, Yoon SY, Oh JH, Yang JO, Kim JH, Song KS, Rho SM, Yoo HS, Kim YS, Kim JG, Kim NS, Clin Cancer Res 2005 11 473 482 15701830 (Pubitemid 40116869)
15. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Ouellet VGM, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM, Int J Cancer 2006 119 599 607 10.1002/ijc.21902 16572426 (Pubitemid 43955714)
16. CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Nakamura Y, Matsuda K, Oncogene 2008 27 1562 1571 10.1038/sj.onc.1210799 17873905 (Pubitemid 351347882)
17. Identification of frequent impairment of the mitotic checkpoint and molecular analysis of the mitotic checkpoint genes, hsMAD2 and p55CDC, in human lung cancers. Takahashi T, Haruki N, Nomoto S, Masuda A, Saji S, Osada H, Oncogene 1999 18 4295 4300 10.1038/sj.onc.1202807 10439037 (Pubitemid 29392370)
18. Frequent impairment of the spindle assembly checkpoint in hepatocellular carcinoma. Saeki A, Tamura S, Ito N, Kiso S, Matsuda Y, Yabuuchi I, Kawata S, Matsuzawa Y, Cancer 2002 94 2047 2054 10.1002/cncr.10448 11932908 (Pubitemid 34270059)
19. Two different mitotic checkpoint inhibitors of the anaphase-promoting complex/cyclosome antagonize the action of the activator Cdc20. Eytan E, Braunstein I, Ganoth D, Teichner A, Hittle JC, Yen TJ, Hershko A, Proc Natl Acad Sci USA 2008 105 9181 9185 10.1073/pnas.0804069105 18591651
20. Under arrest in mitosis: Cdc20 dies twice. Fry AM, Yamano H, Nat Cell Biol 2008 10 1385 1387 10.1038/ncb1208-1385 19043431
21. The APC/C maintains the spindle assembly checkpoint by targeting Cdc20 for destruction. Nilsson J, Yekezare M, Minshull J, Pines J, Nat Cell Biol 2008 10 1411 1420 10.1038/ncb1799 18997788
22. Spindle assembly checkpoint and centrosome abnormalities in oral cancer. Thirthagiri E, Robinson CM, Huntley S, Davies M, Yap LF, Prime SS, Paterson IC, Cancer Lett 2007 258 276 285 10.1016/j.canlet.2007.09.008 17959302 (Pubitemid 350101025)
23. HTLV-I Tax directly binds the Cdc20-associated anaphase-promoting complex and activates it ahead of schedule. Liu B, Hong S, Tang Z, Yu H, Giam CZ, Proc Natl Acad Sci USA 2005 102 63 68 10.1073/pnas.0406424101 15623561 (Pubitemid 40094429)
24. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Li D, Zhu J, Firozi PF, Abbruzzese JL, Evans DB, Cleary K, Friess H, Sen S, Clin Cancer Res 2003 9 991 997 12631597 (Pubitemid 36323702)
25. HSF1 as a mitotic regulator: Phosphorylation of HSF1 by Plk1 is essential for mitotic progression. Lee YJ, Kim EH, Jae SL, Jeoung D, Bae S, Seung HK, Lee YS, Cancer Res 2008 68 7550 7560 10.1158/0008-5472.CAN-08-0129 18794143
26. Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP. Yuan Y, Liao YM, Hsueh CT, Mirshahidi HR, J Hematol Oncol 2011 4 16 10.1186/1756-8722-4- 16 21504625